RT Journal Article SR Electronic T1 Influence of IL2RA rs2104286 Polymorphism in the Risk of Biopsy-proven Giant Cell Arteritis JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 2331 OP 2333 DO 10.3899/jrheum.100388 VO 37 IS 11 A1 LUIS RODRÍGUEZ-RODRÍGUEZ A1 SANTOS CASTAÑEDA A1 TOMÁS R. VÁZQUEZ-RODRÍGUEZ A1 INMACULADA C. MORADO A1 BEATRIZ MARÍ-ALFONSO A1 CARMEN GÓMEZ-VAQUERO A1 JOSÉ A. MIRANDA-FILLOY A1 NORBERTO ORTEGO-CENTENO A1 JAVIER NARVAEZ A1 RICARDO BLANCO A1 BENJAMÍN FERNÁNDEZ-GUTIÉRREZ A1 JAVIER MARTÍN A1 MIGUEL A. GONZÁLEZ-GAY YR 2010 UL http://www.jrheum.org/content/37/11/2331.abstract AB Objective. To assess the influence of the IL2RA rs2104286 A>G polymorphism on susceptibility to and clinical spectrum of manifestations of biopsy-proven giant cell arteritis (GCA). Methods. Our study included 318 patients with biopsy-proven GCA. DNA from patients and healthy controls was obtained from peripheral blood. Samples were genotyped for the IL2RA rs2104286 A>G polymorphism using a predesigned TaqMan allele discrimination assay and by PCR amplification. Results. Although GCA patients showed a higher frequency of the minor allele homozygote of IL2RA rs2104286 (GG) compared to controls (5.1% vs 2.8%, respectively; p = 0.06, odds ratio 1.84, 95% confidence interval 0.91–3.70), the allele distribution showed no significant differences between GCA patients and controls. Stratification of GCA patients according to sex or polymyalgia rheumatica, jaw claudication, visual ischemic manifestations, or other severe ischemic complications did not yield significant differences in the allele or genotype frequencies of the IL2RA rs2104286 polymorphism. Conclusion. IL2RA rs2104286 polymorphism does not appear to be a genetic risk factor for susceptibility to biopsy-proven GCA. Also, this polymorphism does not seem to be implicated in the clinical expression of this vasculitis.